Detalhe da pesquisa
1.
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Am J Hematol
; 95(2): E51-E54, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31814152
2.
Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis.
PLoS One
; 16(5): e0251262, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33970955
3.
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 61(9): 2208-2215, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32812822
4.
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.
Blood Adv
; 1(19): 1575-1583, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296798